<DOC>
	<DOCNO>NCT01320605</DOCNO>
	<brief_summary>Compound HP802-247 comprise two topical spray , administer sequentially right another ; deliver suspension fibroblast keratinocytes wound surface . HP802-247 subject large Phase 2 multi-center trial treat venous leg ulcer . The present study enroll five patient suffer venous leg ulcer , fail prolonged course standard wound therapy one advanced technology , would qualify Phase 2 study .</brief_summary>
	<brief_title>Trial Compassionate Use hp802-247 Treat Venous Leg Ulcers Subjects Who Have Failed Multiple Other Healing Technologies</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Chronic ( duration great six month ) open wound diagnose venous leg ulcer basis consultation vascular surgeon and/or venous ultrasound evaluation Patient continuous care Overlook Hospital Wound Healing Program least four month treatment study lesion ( ) Total study wind surface area great equal 12 cm2 , less 48 cm2 Wounds must fail heal despite patient 's compliance elevation , compression regular debridement , well least one advanced wound therapy ( example , bioengineered dress Oasis速 MatriStem速 , lowfrequency ultrasound , culture skin substitute ( Apligraf速 , Dermagraft速 ) Patient reasonable likelihood heal additional attempt treat FDAapproved product treatment Patients eligible participate Healthpoint sponsor clinical study HP802247 trial ( IND 13,900 ) Patients previously treat HP802247 Women childbearing potential Patients allergic component HP802247</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>